Table 1.
Efficacy of antibody drugs for treatment of atopic dermatits (AD) in clinical trials.
| Target | Antibody drugs | EASI-50 | EASI-75 | IGA 0/1 | Adverse events | Reference |
|---|---|---|---|---|---|---|
| IL-4/IL-13 | Dupilumab | 85% vs. 35% 70.7% vs. 28.9% 69% vs. 20% |
62% vs. 15% 57.3% vs. 14.5% 53% vs. 11% |
40% vs. 7% 26.8% vs. 4.8% 28% vs. 4% |
Conjunctivitis, nasopharyngitis, upper respiratory tract infection, oral herpes, injection-site reaction, headache, transient eosinophilia | (26) (25) (27) |
| IL-13 | Tralokinumab | 73.4% vs. 51.9% N.A. |
42.5% vs. 15.5% 33.2% vs. 11.4% |
N.A. 22.2% vs. 10.9% |
Conjunctivitis, keratitis, headache, upper respiratory tract infection, inject-site reation, keratoconjunctivitis | (28) (29) |
| Lebrikizumab | 82.4% vs. 62.3% 81.0% vs. 45.8% |
54.9% vs. 34.0% 60.6% vs. 24.3% |
33.3% vs. 18.9% 44.6% vs. 15.3% |
Conjunctivitis, injection-site reaction, headache, nasopharyngitis, upper respiratory tract infection, herpesvirus infection | (30) (31) |
|
| Eblasakimab | 85% vs. 40% | 67.0% vs. 0% | 22.0% vs. 0% | N.A. | ||
| IL-22 | Fezakinumab | N.A. | N.A. | 15% vs. 5% | Upper respiratory tract infection | (32) |
| IL-31 | Nemolizumab | 53.7% vs. 39.7% N.A. 79.7% vs. 75.0% |
43.6% vs. 20.9% 50.0% vs. 15.9% 66.4% vs. 59.7% |
N.A. 32.0% vs. 6.8% 28.7% vs. 16.7% |
Injection-site reaction, upper respiratory tract infection | (33) (34) (35) |
| IL-33 | Etokimab | 83.3% | 33% | 25% | Headache, upper respiratory tract infection, conjunctivitis | (36) |
| IGE | Omalizumab | N.A. | N.A. | N.A. | Infective episodes, AD exacerbation, respiratory events | (37) |
| TSLP | Tezepelumab | 64.7% vs. 48.2% | 36.9% vs. 21.9% | 29.4% vs. 12.9% | Nasopharyngitis, injection-site erythema, diarrhea, upper respiratory tract infection, headache | (38) |
| IL-17 | Secukinumab | N.A. | N.A. | N.A. | orbital cellulitis, upper respiratory infection, streptococcal pharyngitis | (39) |
| IL-5 | Mepolizumab (week 12) | 45% vs. 18% | 36% vs. 9% | 11% vs. 0% | N.A. | (40) |
| OX40 | Rocatinlimab | 65% | 55% | 35% | Pyrexia, chills, aphthous ulcer, nasopharyngitis, erythema, hordeolum | (41) |
| 69% vs. 30% | 54% vs. 11% | 31% vs. 2% | (42) | |||
| GBR830 | 76.9% vs. 37.5% | 42.3% vs. 25.0% | 23.1% vs. 12.5% | Headache, nasopharyngitis, upper respiratory tract infection, postprocedual infection, fatigue, myalgia |
(43) | |
| Amlitelimab | N.A. | 59% vs. 25% | N.A. | Infected dermal cyst | (44) |